Board-certified ophthalmologist providing advanced macular degeneration diagnosis and treatment in Roslyn Heights, Nassau County, and the North Shore of Long Island. 

Macular degeneration is a chronic eye condition that affects the macula, the central portion of the retina responsible for sharp, detailed vision. It can interfere with reading, driving, recognizing faces, and other daily activities. The condition is most commonly age-related and may progress gradually or, in some cases, more rapidly.

At Politi Eyecare & Aesthetics, macular degeneration is managed with a comprehensive, evidence-based approach focused on preserving vision and slowing disease progression. Advanced retinal imaging is used to accurately diagnose the type and severity of macular degeneration and guide individualized treatment planning.

Treatment recommendations depend on whether dry (non-neovascular) or wet (neovascular) macular degeneration is present and may include monitoring, nutritional guidance, laser-based therapies, or intravitreal injections when indicated.

Geographic atrophy (GA) is an advanced form of dry macular degeneration characterized by progressive loss of retinal cells in the macula, leading to permanent central vision loss over time. Unlike wet macular degeneration, GA does not involve abnormal blood vessel growth, but it can still significantly impact visual function and quality of life.

Recent advances in ophthalmology have introduced new intravitreal treatment options for geographic atrophy, designed to slow the progression of retinal damage in select patients. These therapies do not restore lost vision but may help preserve remaining retinal function when initiated at appropriate stages of disease.

At Politi Eyecare & Aesthetics, patients with geographic atrophy undergo detailed retinal imaging and evaluation to determine whether emerging treatment options may be appropriate. Treatment decisions are individualized and based on disease severity, progression risk, and overall ocular health.

 Intravitreal injections are a primary treatment for wet macular degeneration and work by reducing abnormal blood vessel growth and retinal fluid leakage. These medications are delivered directly into the eye under sterile conditions and are used to stabilize or improve vision in many patients. Treatment frequency is individualized based on disease activity and response. 

 In select cases, laser-based treatments may be used to manage certain complications related to macular degeneration. These procedures are carefully selected based on retinal findings and are performed to help preserve remaining vision and reduce disease progression.